南方科技大学知识苑(SUSTech KC): Inhibition of hepatic NLRP3 inflammasome ameliorates non-alcoholic steatohepatitis/ hepatitis B-induced hepatic injury

题名	Inhibition of hepatic NLRP3 inflammasome ameliorates non-alcoholic steatohepatitis/ hepatitis B-induced hepatic injury
作者	Chen, Feng 1,2 ; Liu, Yingxia 2; Li, Qianhui 1; Wang, Fei 1
通讯作者	Wang, Fei
发表日期	2023
DOI	10.1016/j.clinre.2022.102056
发表期刊	CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY 影响因子和分区
ISSN	2210-7401
EISSN	2210-741X
卷号	47 期号:1
摘要	Background and aim: Both chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) are the most common liver diseases over the world, but their underlying pathological mechanisms and interrelations are poorly understood. Methods: Histological analysis and NLRP3 protein expression were performed on 130 CHB patients with liver-biopsied. Wild-type or NLRP3 knockdown hepatitis B virus (HBV) -transgenic mice were fed with high-fat diet to induce steatosis, with or without co-administration with a novel NLRP3 inhibitor MCC950. Results: Hepatic NLRP3 inflammasome is markedly up-regulated in the CHB, NASH, superimposed NASH with CHB patients and their corresponding model mice. Hepatic knock-down of NLRP3 significantly inhibits HBV replication and surface antigen expression, as well as ameliorates NASH typical symptoms of HBV transgenic mice with or without high-fat diet consumption. In addition, administration of MCC950 successfully inhibits pathological features of both CHB and steatosis-induced liver damage without detectable adverse effects. Conclusions: NLRP3 inflammasome is activated during the progression of both CHB and NASH and may play a critical role in their pathogenesis by regulating hepatic inflammation. Targeting this protein platform may represent an effective and novel strategy for the treatment of CHB, NASH and the superimposed patients. (c) 2022 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
关键词	HBV Steatosis MCC950 NLRP3
相关链接	[来源记录]
收录类别	SCI
语种	英语
学校署名	其他
资助项目	National Natural Science Foundation of China["81873573","81873578"]
WOS研究方向	Gastroenterology & Hepatology
WOS类目	Gastroenterology & Hepatology
WOS记录号	WOS:000992203700001
出版者	ELSEVIER MASSON, CORP OFF
来源库	Web of Science
引用统计	被引频次[WOS]：5
成果类型	期刊论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/583114
专题	南方科技大学第二附属医院
作者单位	1.Sun Yat Sen Univ, Affiliated Hosp 7, Div Gastroenterol, 628 Zhenyuan Rd, Shenzhen 518107, Peoples R China 2.Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, Hosp Affiliated 2, Shenzhen 518112, Peoples R China
第一作者单位	南方科技大学第二附属医院
推荐引用方式 GB/T 7714	Chen, Feng,Liu, Yingxia,Li, Qianhui,et al. Inhibition of hepatic NLRP3 inflammasome ameliorates non-alcoholic steatohepatitis/ hepatitis B-induced hepatic injury[J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY,2023,47(1).
APA	Chen, Feng,Liu, Yingxia,Li, Qianhui,&Wang, Fei.(2023).Inhibition of hepatic NLRP3 inflammasome ameliorates non-alcoholic steatohepatitis/ hepatitis B-induced hepatic injury.CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY,47(1).
MLA	Chen, Feng,et al."Inhibition of hepatic NLRP3 inflammasome ameliorates non-alcoholic steatohepatitis/ hepatitis B-induced hepatic injury".CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY 47.1(2023).